Skip to main content
Intracranial MeningiomaGeneticsDrugPhase 2

What this study is

This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

What's being tested

  • Vismodegib

    Intervention · DRUG

  • FAK Inhibitor GSK2256098

    Intervention · DRUG

  • Capivasertib

    Intervention · DRUG

  • Abemaciclib

    Intervention · DRUG

All interventions

Given PO

Study details

Official title
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Sponsor
Alliance for Clinical Trials in Oncology
Conditions
Intracranial Meningioma · Recurrent Meningioma · NF2 Gene Mutation
Enrolling
124 people
Starts
2015-09-28
Est. completion
2029-06-01
Design
Open-label, non-randomized, parallel groups, Phase 2
Record
View on ClinicalTrials.gov ↗